CCEL

Cryo-Cell International, Inc. - 10-Q Summary

Business Context and Reporting Period

Company: Cryo-Cell International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: February 28, 2011
Business Overview: The Company is engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells (U-Cord) and menstrual stem cells (C'ellé). Revenue is derived from processing/storage fees and licensing royalties from international affiliates.

Key Financial Metrics

Margins: Cost of sales was 26% of processing and storage fee revenue. Gross margin on total revenue was approximately 74%.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 4% year-over-year. This was driven by an 8% increase in processing and storage fees (due to a 10% increase in specimens processed) but was partially offset by a 28% decrease in licensee income due to timing of fee payments.
• Profitability Decline: Net income decreased 37% to $233,419. This decline was primarily caused by an 8% increase in marketing, general, and administrative expenses and a 6% increase in cost of sales.
• Expense Reductions: Research and development expenses decreased 32% to $35,622.
• Cash Flow Improvement: Operating cash flow turned positive ($237,758) compared to a negative outflow ($62,063) in the prior year, largely due to net income generation and the absence of a large one-time sponsorship payment made in the prior year.

Guidance, Outlook, and Risks

Accounting Change: The Company retrospectively adopted a new FASB accounting standard regarding revenue recognition for multiple deliverable arrangements. This changed how discounts are allocated between processing and storage fees, resulting in adjustments to prior period financial statements to ensure comparability.

Liquidity and Capital Resources: The Company holds approximately $8.4 million in cash and cash equivalents with no long-term indebtedness. Management anticipates that current cash and operating cash flows will be sufficient to fund operations for at least the next 12 months. Anticipated capital expenditures are approximately $750,000 over the next year.

Legal Proceedings: The Company is involved in litigation against Cord Blood America, Inc. (CBAI) and Cryo-Cell de Mexico (CCMEX) regarding a proposed acquisition of CCMEX assets that the Company believes violates its exclusive license agreement. On March 18, 2011, the court granted motions to dismiss filed by the defendants. The Company is evaluating legal alternatives to enforce its rights.

Risks: Key risks include regulatory changes in stem cell storage, increased competition from public banks, market acceptance of new technologies (C'ellé), and the success of international licensing agreements. The Company also faces risks related to the collectability of licensee fees and potential impairment of its investment in Saneron CCEL Therapeutics, Inc.

Investor Verification Checklist

• Revenue Recognition Policy: Verify the impact of the retrospective adoption of the new accounting standard on future revenue recognition and comparability.
• Licensee Collectability: Review the status of outstanding payments from international licensees (e.g., Pakistan, Germany/IMS) where revenue recognition has been delayed or disputed.
• Legal Outcome: Monitor the status of the litigation against CBAI and CCMEX, as a loss could impact the Company's exclusive rights in the Mexican market.
• Deferred Revenue: Note the significant deferred revenue balance ($12.4 million total), which represents future obligations and revenue recognition over long storage periods.
• Stock Compensation: Review the $59,000 stock compensation expense and the $171,214 of unrecognized compensation cost related to non-vested options.